Basic Stats
| LEI | 635400OP2DYYYMOIYL17 |
| CIK | 1420800 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Colfax Corp
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 7, 2025 |
Exhibit 31.1 CERTIFICATIONS I, Damien McDonald, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respe |
|
| August 7, 2025 |
Enovis Announces Second Quarter 2025 Results Enovis Announces Second Quarter 2025 Results •Continued commercial momentum with second-quarter sales growth of 7% on a reported basis •Second-quarter Reconstructive sales grew 11% year-over-year on a reported basis WILMINGTON, DE, August 7, 2025 (GLOBE NEWSWIRE)—Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction (Commission (I.R.S. Employer of inc |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 4, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34045 Enovis Corporation (Ex |
|
| August 7, 2025 |
Exhibit 32.2 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Phillip B. Berry, as Senior Vice President and Chief Financial Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.the quarterly |
|
| August 7, 2025 |
Exhibit 31.2 CERTIFICATIONS I, Phillip B. Berry, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with resp |
|
| August 7, 2025 |
Exhibit 32.1 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Damien McDonald, as Chief Executive Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.the quarterly report on Form 10-Q of the |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number - 001-34045 A. Full title of the plan and the ad |
|
| May 30, 2025 |
SD United States Securities and Exchange Commission Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 (State or other jurisdiction of incorporation) (Commission file number) 2711 Centerville Road, Suite 400 Wilmington, DE 19808 20701 (Address of principal executive offices) (Zip code) Bradley J. |
|
| May 30, 2025 |
EX-1.01 Exhibit 1.01 Conflict Minerals Report Enovis Corporation has included this Conflict Minerals Report as an exhibit to its Form SD for the period from January 1, 2024 to December 31, 2024 as provided for in Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and Form SD (collectively, the “Conflict Minerals Rule”). Unless the context indicates otherwise, the terms “Enovis,” “we |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 8, 2025 |
Exhibit 31.2 CERTIFICATIONS I, Phillip B. Berry, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with resp |
|
| May 8, 2025 |
Exhibit 32.2 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Phillip B. Berry, as Senior Vice President and Chief Financial Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.the quarterly |
|
| May 8, 2025 |
Exhibit 31.1 CERTIFICATIONS I, Matthew L. Trerotola, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 4, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34045 Enovis Corporation (E |
|
| May 8, 2025 |
Damien McDonald Offer Letter – Page 1 Damien McDonald Offer Letter – Page 1 of 4 February 27, 2025 Mr. Damien McDonald Via Email Strictly private and confidential Dear Damien, Congratulations! We are very pleased to extend you an employment offer for the position of Chief Executive Officer, Enovis Corporation (“Enovis”), reporting to the Board of Directors of Enovis Corporation (the “Board”). This offer letter (the “Offer”) has been a |
|
| May 8, 2025 |
Enovis Announces First Quarter 2025 Results Enovis Announces First Quarter 2025 Results •Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion •First-quarter Reconstructive sales grew 11% year-over-year on a reported basis •Appointed Damien McDonald as CEO, effective May 12th, 2025 WILMINGTON, DE, May 8, 2025 (GLOBE NEWSWIRE)—Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. |
|
| May 8, 2025 |
Exhibit 32.1 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Matthew L. Trerotola, as President and Chief Executive Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.the quarterly report o |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction (Commission (I.R.S. Employer of incorp |
|
| April 11, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| April 11, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File N |
|
| April 2, 2025 |
Enovis Announces Appointment of Damien McDonald as Chief Executive Officer Exhibit 99.1 Enovis Announces Appointment of Damien McDonald as Chief Executive Officer • Damien McDonald appointed CEO, effective as of May 12, 2025 • Company reiterates guidance for first quarter revenues and aEBITDA WILMINGTON, DE, April 2, 2025 (GLOBE NEWSWIRE) — Enovis™ Corporation (“Enovis” or “The Company”) (NYSE: ENOV), a leader in medical technology innovation, today announced the appoint |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File |
|
| March 14, 2025 |
Retirement and Transition Agreement dated March 13, 2025 EX-10.1 Exhibit 10.1 March 13, 2025 Mr. Matthew L. Trerotola [Address on file with the Company] Re: CEO Retirement and Transition Agreement Dear Matt: In connection with your notice to the Board of Directors (the “Board”) of Enovis Corporation (the “Company”) of your intention to retire from your current role as Chief Executive Officer (“CEO”) of the Company, effective upon the date that the Board |
|
| February 26, 2025 |
Form of Performance Stock Unit Agreement Enovis Corporation Exhibit 10.28 2020 Omnibus Incentive Plan Form of Performance Stock Unit Agreement Enovis Corporation, a Delaware corporation (the “Company”), hereby grants stock units relating to shares of its common stock, $.001 par value (the “Stock”), to the individual named below as the Grantee. The terms and conditions of the grant are set forth in this Performance Stock Unit Agreement (t |
|
| February 26, 2025 |
Form Of Restricted Stock Unit Agreement Enovis Corporation Exhibit 10.29 2020 Omnibus Incentive Plan Form Of Restricted Stock Unit Agreement Enovis Corporation, a Delaware corporation (the “Company”), hereby grants stock units relating to shares of its common stock, $.001 par value (the “Stock”), to the individual named below as the Grantee. The terms and conditions of the grant are set forth in this Restricted Stock Unit Agreement (the |
|
| February 26, 2025 |
Enovis Corporation Subsidiaries of the Registrant Exhibit 21.1 Enovis Corporation Subsidiaries of the Registrant Entity Name Domestic Jurisdiction Country 360 Hip Systems Pty Limited Australia Australia 360 Knee Systems (NZ) Limited New Zealand New Zealand 360 Knee Systems Pty Ltd Australia Australia 360 Med Care Pty Ltd Australia Australia Armac, Inc. New Jersey United States Athena Finance Limited Barbados Barbados Cefar-Compex Medical AB Swede |
|
| February 26, 2025 |
Exhibit 4.2 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Enovis Corporation (the “Company,” “we,” “us” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, $0.001 par value per share (the “common stock”). Description of Commo |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction (Commission (I.R.S. Employer of |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2025 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34045 ENOVIS CORPORATION (Exact |
|
| February 26, 2025 |
Enovis Announces Planned CEO Succession Process Exhibit 99.1 Enovis Announces Planned CEO Succession Process WILMINGTON, DE, February 26, 2025 (GLOBE NEWSWIRE)—Enovis™ Corporation (“Enovis” or the “Company”) (NYSE: ENOV), a leader in medical technology innovation, announced today that Matt Trerotola has informed the Board of Directors (the “Board”) of his intention to retire from his position as Chief Executive Officer (CEO) of Enovis, effectiv |
|
| February 26, 2025 |
Enovis Announces Fourth Quarter and Full Year 2024 Results Enovis Announces Fourth Quarter and Full Year 2024 Results •Continued commercial momentum with fourth-quarter sales growth of 23% on a reported basis and strong adjusted EBITDA margin expansion •Fourth-quarter Reconstructive sales grew 59% Y/Y on a reported basis and 10% on a Comparable Sales basis •Exceeded year one commercial and integration plans for Lima WILMINGTON, DE, February 26, 2025 (GLOBE NEWSWIRE)—Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2024. |
|
| February 26, 2025 |
ENOVIS CORPORATION Insider Trading Compliance Policy Exhibit 19.1 ENOVIS CORPORATION Insider Trading Compliance Policy Enovis Corporation and its subsidiaries (collectively, the “Company”) seek to promote a culture that encourages ethical conduct and a commitment to compliance with the law. We require our personnel to comply at all times with federal laws and regulations governing insider trading. This policy sets forth procedures designed to help c |
|
| February 26, 2025 |
Form of Non-Qualified Stock Option Agreement Enovis Corporation Exhibit 10.27 2020 Omnibus Incentive Plan Form of Non-Qualified Stock Option Agreement Enovis Corporation, a Delaware corporation (the “Company”), hereby grants an option to purchase shares of its common stock, $.001 par value, (the “Stock”) to the optionee named below. The terms and conditions of the option are set forth in this Non-Qualified Stock Option Agreement (the “Agreem |
|
| January 28, 2025 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(7) (Form Type) Enovis Corporation (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, par value $0. |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 28, 2025 |
ENOVIS CORPORATION 971,343 SHARES OF COMMON STOCK Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-277239 Prospectus Supplement ENOVIS CORPORATION 971,343 SHARES OF COMMON STOCK This prospectus supplement relates to the resale from time to time of up to 971,343 shares of common stock, par value $0.001 per share, of Enovis Corporation, a Delaware corporation (“Enovis,” “we,” “us” or “our”), by the selling stockholder named i |
|
| January 13, 2025 |
2025 JP Morgan Healthcare Conference Matt Trerotola Chair, Chief Executive Officer Ben Berry Chief Financial Officer Kyle Rose Vice President, Investor Relations Exhibit 99. |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 6, 2024 |
Exhibit 31.2 CERTIFICATIONS I, Phillip B. Berry, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with resp |
|
| November 6, 2024 |
Exhibit 32.2 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Phillip B. Berry, as Senior Vice President and Chief Financial Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.the quarterly |
|
| November 6, 2024 |
Exhibit 31.1 CERTIFICATIONS I, Matthew L. Trerotola, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| November 6, 2024 |
Enovis Announces Third Quarter 2024 Results Enovis Announces Third Quarter 2024 Results •Continued commercial momentum with third-quarter sales growth of 21% on a reported basis and strong adjusted EBITDA margin expansion •Reconstructive sales grew 57% Y/Y on a reported basis and 9% on a Comparable basis •Reported third-quarter net loss from continuing operations of $0. |
|
| November 6, 2024 |
Exhibit 32.1 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Matthew L. Trerotola, as President and Chief Executive Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.the quarterly report o |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 27, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34045 Enovis Corporati |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction (Commission (I.R.S. Employer of i |
|
| August 7, 2024 |
Enovis Corporation Subsidiaries of the Registrant Exhibit 21.1 Enovis Corporation Subsidiaries of the Registrant Entity Name Domestic Jurisdiction Country 360 Hip Systems Pty Limited Australia Australia 360 Knee Systems (NZ) Limited New Zealand New Zealand 360 Knee Systems Pty Ltd Australia Australia 360 Med Care Pty Ltd Australia Australia Athena Finance Limited Barbados Barbados Cefar-Compex Medical AB Sweden Sweden Chattanooga Europe, B.V. Bel |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 28, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34045 Enovis Corporation (E |
|
| August 7, 2024 |
Exhibit 32.2 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Phillip B. Berry, as Senior Vice President and Chief Financial Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.the quarterly |
|
| August 7, 2024 |
Exhibit 32.1 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Matthew L. Trerotola, as President and Chief Executive Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.the quarterly report o |
|
| August 7, 2024 |
Exhibit 31.1 CERTIFICATIONS I, Matthew L. Trerotola, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| August 7, 2024 |
Exhibit 31.2 CERTIFICATIONS I, Phillip B. Berry, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with resp |
|
| August 7, 2024 |
Enovis Announces Second Quarter 2024 Results Enovis Announces Second Quarter 2024 Results •Continued strong momentum with second-quarter sales growth of 23% on a reported basis and strong adjusted margin expansion •Reported second-quarter net loss from continuing operations of $0. |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction (Commission (I.R.S. Employer of inc |
|
| July 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2024 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File N |
|
| July 18, 2024 |
EX-FILING FEES 2 d400821dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(7) (Form Type) Enovis Corporation (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregat |
|
| July 18, 2024 |
ENOVIS CORPORATION 971,343 SHARES OF COMMON STOCK 424B7 1 d400821d424b7.htm 424B7 Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-277239 Prospectus Supplement ENOVIS CORPORATION 971,343 SHARES OF COMMON STOCK This prospectus supplement relates to the resale from time to time of up to 971,343 shares of common stock, par value $0.001 per share, of Enovis Corporation, a Delaware corporation (“Enovis,” “we,” “us” or “our”), by |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number - 001-34045 A. Full title of the plan and the ad |
|
| June 26, 2024 |
As filed with the Securities and Exchange Commission on June 26, 2024 As filed with the Securities and Exchange Commission on June 26, 2024 Registration No. |
|
| June 26, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) ENOVIS CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0. |
|
| May 31, 2024 |
United States Securities and Exchange Commission Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 (State or other jurisdiction of incorporation) (Commission file number) 2711 Centerville Road, Suite 400 Wilmington, DE 19808 20701 (Address of principal executive offices) (Zip code) Bradley J. Ta |
|
| May 31, 2024 |
Exhibit 1.01 Conflict Minerals Report Enovis Corporation has included this Conflict Minerals Report as an exhibit to its Form SD for the period from January 1, 2023 to December 31, 2023 as provided for in Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and Form SD (collectively, the “Conflict Minerals Rule”). Unless the context indicates otherwise, the terms “Enovis,” “we,” “its, |
|
| May 22, 2024 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATERD CERTIFICATE OF INCORPORATION OF ENOVIS CORPORATION Enovis Corporation, a corporation duly organized and validly existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: The Amended and Restated Certificate of Incorporation of the Corporation, as |
|
| May 22, 2024 |
Second Amendment to Enovis Corporation 2020 Omnibus Incentive Plan Exhibit 10.1 SECOND AMENDMENT TO THE ENOVIS CORPORATION 2020 OMNIBUS INCENTIVE PLAN WHEREAS, Enovis Corporation, a Delaware corporation, formerly named Colfax Corporation (the “Company”), established and sponsors the Enovis Corporation 2020 Omnibus Incentive Plan, as amended (the “Plan”); WHEREAS, pursuant to Section 5.3 of the Plan, the Board of Directors of the Company (the “Board”) reserved the |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 2, 2024 |
Exhibit 31.1 CERTIFICATIONS I, Matthew L. Trerotola, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| May 2, 2024 |
Exhibit 32.1 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Matthew L. Trerotola, as President and Chief Executive Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.the quarterly report o |
|
| May 2, 2024 |
Exhibit 31.2 CERTIFICATIONS I, Phillip B. Berry, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with resp |
|
| May 2, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction (Commission (I.R.S. Employer of incorp |
|
| May 2, 2024 |
Enovis Announces First Quarter 2024 Results Enovis Announces First Quarter 2024 Results •Strong start to the year with sales growth of 27% on a reported basis and strong adjusted margin expansion •Reported first-quarter net loss from continuing operations of $1. |
|
| May 2, 2024 |
Exhibit 32.2 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Phillip B. Berry, as Senior Vice President and Chief Financial Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.the quarterly |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 29, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34045 Enovis Corporation ( |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pr |
|
| April 5, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| March 25, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| February 22, 2024 |
Calculation of Filing Fee Tables. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Enovis Corporation (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Debt Debt Securities Rule 456(b) Rule 457(r) (1) (1) (1) (2) (2) Equity Common Stock, par value $0. |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34045 ENOVIS CORPORATION (Exact |
|
| February 22, 2024 |
ENOVIS CORPORATION POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION ENOVIS CORPORATION POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Enovis Corporation (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of September 20, 2023 (the “Effective Date”). |
|
| February 22, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction (Commission (I.R.S. Employer of |
|
| February 22, 2024 |
REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT, dated as of January 3, 2024 (this “Agreement”), is by and between Enovis Corporation, a Delaware corporation (“Enovis”), and Emil Holding II S. |
|
| February 22, 2024 |
Enovis Announces Fourth Quarter and Full Year 2023 Results Enovis Announces Fourth Quarter and Full Year 2023 Results •Continued strong momentum with fourth-quarter sales growth of 11%, organic growth of 8% •Reported a fourth-quarter net income from continuing operations of $0. |
|
| February 22, 2024 |
As filed with the Securities and Exchange Commission on February 22, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 22, 2024 Registration No. |
|
| February 22, 2024 |
Enovis Corporation Subsidiaries of the Registrant Exhibit 21.1 Enovis Corporation Subsidiaries of the Registrant Entity Name Domestic Jurisdiction Country 360 EPPA Pty Ltd Australia Australia 360 Hip Systems Pty Limited Australia Australia 360 Knee Systems (NZ) Limited New Zealand New Zealand 360 Knee Systems Pty Ltd Australia Australia 360 Med Care Pty Ltd Australia Australia Aevumed, Inc. Delaware United States Athena Finance Limited Barbados B |
|
| February 21, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporati |
|
| February 21, 2024 |
Exhibit 99.1 Consolidated financial statements restated as at 31 December 2022 Contents Consolidated financial statements restated as at 31 December 2022 of the Limacorporate Group 3 Notes to the Consolidated financial statements restated as at 31 December 2022 8 Other information 48 2022 2 Consolidated financial statements restated as at 31 December 2022 of the Limacorporate Group Statement of fi |
|
| February 21, 2024 |
Exhibit 99.2 Condensed consolidated interim financial statements as of and for the nine-months ended 30 September 2023 Contents Condensed consolidated statement of financial position 3 Condensed consolidated income statement 4 Condensed consolidated statement of comprehensive income 5 Condensed consolidated statement of changes in equity 6 Condensed consolidated statement of cash flows 7 Notes to |
|
| February 21, 2024 |
ENOVIS CORPORATION UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION SEPTEMBER 30, 2023 Exhibit 99.3 ENOVIS CORPORATION UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION SEPTEMBER 30, 2023 1 UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET As of September 30, 2023 ($ in thousands) Enovis Historical As of September 30, 2023 Lima Historical As of September 30, 2023 (Note 2) Transaction Accounting Adjustments Note 4 Financing Adjustments Note 4 Pro Forma Combined ASSETS C |
|
| February 13, 2024 |
ENOV / Enovis Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0848-enoviscorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Enovis Corp Title of Class of Securities: Common Stock CUSIP Number: 194014502 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pur |
|
| February 12, 2024 |
ENOV / Enovis Corporation / Durable Capital Partners LP - AMENDMENT TO SC 13G Passive Investment SC 13G/A 1 enovissc13ga-123123.htm AMENDMENT TO SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Enovis Corporation (Name of Issuer) Common Stock, $0.001 per share (Title of Class of Securities) 194014502 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) |
|
| February 9, 2024 |
ENOV / Enovis Corporation / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Enovis Corp (Name of Issuer) Common Stock (Title of Class of Securities) 194014502 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File |
|
| January 8, 2024 |
EX-99.1 Matt Trerotola Chairman, Chief Executive Officer 2024 JP Morgan Healthcare Conference Ben Berry Chief Financial Officer Kyle Rose Vice President, Investor Relations Exhibit 99.1 Enovis has provided in this presentation financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America (“non-GAAP”). These non-GAAP fin |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File |
|
| January 3, 2024 |
Enovis Completes Acquisition of LimaCorporate S.p.A Exhibit 99.1 News Release Enovis Completes Acquisition of LimaCorporate S.p.A WILMINGTON, DE, January 3, 2024 (GLOBE NEWSWIRE)—Enovis™ Corporation (NYSE: ENOV, “Enovis” or the “Company”) an innovation-driven, medical technology growth company, today announced that it closed the acquisition of LimaCorporate S.p.A. (“Lima”), a privately held global orthopedic leader focused on restoring motion throu |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 5, 2023 |
Enovis Announces Business Segment Leadership Transition Plan Exhibit 99.1 Enovis Announces Business Segment Leadership Transition Plan • Brady R. Shirley, current President and COO, to retire effective April 1, 2025. • Louie Vogt to be promoted to Group President of Reconstructive segment. • Terry Ross to be promoted to Group President of Prevention & Recovery segment. Wilmington, Delaware, December 5, 2023 — Enovis Corporation (NYSE: ENOV), an innovation-d |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction (Commission (I.R.S. Employer of i |
|
| November 7, 2023 |
Enovis Announces Third Quarter 2023 Results and Raises Full-Year Outlook Enovis Announces Third Quarter 2023 Results and Raises Full-Year Outlook •Continued strong momentum with third quarter sales growth of 9% and strong adjusted EBITDA margin expansion •Organic growth of 10% in Recon and 4% in P&R •Reported a third quarter net loss from continuing operations of $0. |
|
| November 7, 2023 |
Exhibit 31.2 CERTIFICATIONS I, Phillip B. Berry, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with resp |
|
| November 7, 2023 |
JPMORGAN CHASE BANK, N.A. 383 Madison Avenue New York, New York 10179 JPMORGAN CHASE BANK, N.A. 383 Madison Avenue New York, New York 10179 UBS AG, STAMFORD BRANCH 600 Washington Boulevard Stamford, Connecticut 06901 UBS SECURITIES LLC 1285 Avenue of the Americas New York, New York 10019 CONFIDENTIAL September 22, 2023 Project Inca Commitment Letter Enovis Corporation 2711 Centerville Road, Suite 400 Wilmington, DE 19808 Attention: Ben Berry, Chief Financial Officer |
|
| November 7, 2023 |
Exhibit 32.2 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Phillip B. Berry, as Senior Vice President and Chief Financial Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.the quarterly |
|
| November 7, 2023 |
Exhibit 31.1 CERTIFICATIONS I, Matthew L. Trerotola, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| November 7, 2023 |
Exhibit 32.1 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Matthew L. Trerotola, as President and Chief Executive Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.the quarterly report o |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 29, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34045 Enovis Corporati |
|
| October 25, 2023 |
Form of Capped Call Confirmation. Exhibit 10.1 Final Bidding Draft [Dealer’s name] [Dealer’s address]1 [ ], 2023 To: Enovis Corporation 2711 Centerville Road, Suite 400 Wilmington, DE 19808 Attention: [ ] Telephone No.: [ ] Re: [Base][Additional] Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into bet |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 19, 2023 Enovis Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34045 Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| October 25, 2023 |
Exhibit 4.1 Execution Version ENOVIS CORPORATION AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of October 24, 2023 3.875% Convertible Senior Notes due 2028 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 14 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. Design |
|
| October 25, 2023 |
Exhibit 10.2 EXECUTION VERSION AMENDMENT NO. 1 TO CREDIT AGREEMENT This Amendment No. 1 to Credit Agreement, dated as of October 23, 2023 (this “Amendment”) is among Enovis Corporation, a Delaware corporation (the “Lead Borrower”), the financial institutions listed on the signature pages hereof as Lenders, the Guarantors listed on the signature pages hereto and JPMorgan Chase Bank, N.A., as Admini |
|
| October 20, 2023 |
Exhibit 99.1 News Release ENOVIS CORPORATION ANNOUNCES PRICING OF PRIVATE OFFERING OF $400 MILLION OF 3.875% CONVERTIBLE SENIOR NOTES DUE 2028 WILMINGTON, DE, October 20, 2023 (GLOBE NEWSWIRE)—Enovis™ Corporation (NYSE: ENOV, “Enovis” or the “Company”) today announced the pricing of $400 million aggregate principal amount of 3.875% Convertible Senior Notes due 2028 (the “Notes”) in a private offer |
|
| October 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 20, 2023 Enovis Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34045 Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| October 19, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On September 22, 2023, the Company entered into the Lima Acquisition Agreement for a purchase price of approximately $850,000,000 (consisting of €700 million in cash consideration plus up to 1,942,686 Enovis common shares), subject to certain adjustments. The Enovis shares are expected to be issued within 18 months following |
|
| October 19, 2023 |
Exhibit 99.1 KPMG S.p.A. Revisione e organizzazione contabile Piazza Salvemini, 20 35131 PADOVA PD Telefono +39 049 8249101 Email [email protected] PEC [email protected] Independent auditors’ report To the board of directors of Limacorporate S.p.A. Report on the audit of the consolidated financial statements Opinion We have audited the accompanying consolidated financial statements of the Li |
|
| October 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 19, 2023 Enovis Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34045 Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| October 19, 2023 |
Exhibit 99.2 KPMG S.p.A. Revisione e organizzazione contabile Piazza Salvemini, 20 35131 PADOVA PD Telefono +39 049 8249101 Email [email protected] PEC [email protected] Independent Auditors’ report on review of condensed consolidated interim financial statements To the board of directors of Limacorporate S.p.A. Introduction We have reviewed the accompanying condensed consolidated interim fi |
|
| October 19, 2023 |
ENOVIS CORPORATION ANNOUNCES PROPOSED PRIVATE OFFERING OF $400 MILLION OF CONVERTIBLE SENIOR NOTES Exhibit 99.4 News Release ENOVIS CORPORATION ANNOUNCES PROPOSED PRIVATE OFFERING OF $400 MILLION OF CONVERTIBLE SENIOR NOTES WILMINGTON, DE, October 19, 2023 (GLOBE NEWSWIRE)—Enovis™ Corporation (NYSE: ENOV, “Enovis” or the “Company”) today announced its intention to offer, subject to market conditions and other factors, $400 million aggregate principal amount of Convertible Senior Notes due 2028 |
|
| September 28, 2023 |
Exhibit 2.1 22 September 2023 by and among Emil Holding II S.à r.l. as Seller and Enovis Corporation as Purchaser Share purchase agreement related to the sale and purchase of the entire share capital of LimaCorporate S.p.A. Corso Matteotti, 22 Milano 20121 Italy Tel: +39.02.3046.2000 www.lw.com SHARE PURCHASE AGREEMENT This Share Purchase Agreement (the Agreement) is entered into, by and among: (1 |
|
| September 28, 2023 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 22, 2023 Enovis Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34045 Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| September 25, 2023 |
Enovis™ to Acquire LimaCorporate S.p.A. Exhibit 99.1 Enovis™ to Acquire LimaCorporate S.p.A. • Creating a high-growth, global reconstruction leader with ~$1 billion in annual revenue • Attractive margin profile and meaningful synergies expected to increase profitability WILMINGTON, DE, SEPTEMBER 25, 2023 (GLOBE NEWSWIRE)—Enovis™ Corporation (NYSE: ENOV, “Enovis” or the “Company”), an innovation-driven, medical technology growth company, |
|
| September 25, 2023 |
Exhibit 99.2 Advancing strategy through LimaCorporate acquisition September 25, 2023 Forward-looking Statements Non-GAAP Financial Information This presentation includes forward-looking statements, including forward-looking Enovis has provided in this presentation certain financial information that has not been prepared statements within the meaning of the U.S. Private Securities Litigation Reform |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 25, 2023 Enovis Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34045 Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2023 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission F |
|
| September 12, 2023 |
EX-99.1 Exhibit 99.1 Matt Trerotola Chief Executive Officer Ben Berry Chief Financial Officer Forward-looking Statements Non-GAAP Financial Information This presentation includes forward-looking statements, including Enovis has provided in this presentation financial information that has not been prepared in accordance with accounting forward-looking statements within the meaning of the U.S. Priva |
|
| August 3, 2023 |
Exhibit 32.1 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Matthew L. Trerotola, as President and Chief Executive Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.the quarterly report o |
|
| August 3, 2023 |
Exhibit 31.2 CERTIFICATIONS I, Phillip B. Berry, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with resp |
|
| August 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction (Commission (I.R.S. Employer of inc |
|
| August 3, 2023 |
Enovis Announces Second Quarter 2023 Results and Raises Full-Year Outlook Enovis Announces Second Quarter 2023 Results and Raises Full-Year Outlook •Continued strong momentum with second quarter sales growth of 8% and strong EBITDA margin expansion •Organic growth of 17% in Recon and 4% in P&R •Reported a second quarter net loss from continuing operations of $0. |
|
| August 3, 2023 |
Exhibit 31.1 CERTIFICATIONS I, Matthew L. Trerotola, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34045 Enovis Corporation (E |
|
| August 3, 2023 |
Exhibit 32.2 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Phillip B. Berry, as Senior Vice President and Chief Financial Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.the quarterly |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number - 001-34045 A. Full title of the plan and the ad |
|
| June 1, 2023 |
As filed with the Securities and Exchange Commission on June 1, 2023 S-8 As filed with the Securities and Exchange Commission on June 1, 2023 Registration No. |
|
| June 1, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Enovis Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Aggregate Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of registration fee Equity Common Stock, $0. |
|
| May 31, 2023 |
EX-1.01 Exhibit 1.01 Conflict Minerals Report Enovis Corporation has included this Conflict Minerals Report as an exhibit to its Form SD for the period from January 1, 2022 to December 31, 2022 as provided for in Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and Form SD (collectively, the “Conflict Minerals Rule”). The date of filing of this Conflict Minerals Report is May 31, |
|
| May 31, 2023 |
SD United States Securities and Exchange Commission Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 (State or other jurisdiction of incorporation) (Commission file number) 2711 Centerville Road, Suite 400 Wilmington, DE 19808 20701 (Address of principal executive offices) (Zip code) Bradley J. |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 22, 2023 |
Enovis Corporation 2023 Non-Qualified Stock Purchase Plan EX-10.1 Exhibit 10.1 ENOVIS CORPORATION 2023 NON-QUALIFIED STOCK PURCHASE PLAN 1. Purpose. The purpose of the 2023 Non-Qualified Stock Purchase Plan (the “Plan”) is to provide an incentive for Eligible Employees of certain Participating Companies to acquire Stock of the Company through accumulated payroll deductions. The provisions of the Plan are subject to the provisions stated in the Appendices |
|
| May 4, 2023 |
Exhibit 32.2 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Phillip B. Berry, as Senior Vice President and Chief Financial Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.the quarterly |
|
| May 4, 2023 |
Exhibit 31.2 CERTIFICATIONS I, Phillip B. Berry, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with resp |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction (Commission (I.R.S. Employer of incorp |
|
| May 4, 2023 |
Exhibit 32.1 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Matthew L. Trerotola, as President and Chief Executive Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.the quarterly report o |
|
| May 4, 2023 |
Enovis Announces First Quarter 2023 Results EX-99.1 2 q12023earningspressrelease.htm EX-99.1 Enovis Announces First Quarter 2023 Results •Strong start to the year with sales growth of 8%, organic growth of 9% and strong EBITDA margin expansion •Organic growth of 9% reflects 19% organic growth in Recon and 4% organic growth in P&R •Reported a first quarter net loss from continuing operations of $0.42 per share with adjusted earnings per dilu |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34045 Enovis Corporation ( |
|
| May 4, 2023 |
Exhibit 31.1 CERTIFICATIONS I, Matthew L. Trerotola, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| March 31, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| March 31, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 14, 2023 Enovis Corporation (Exact name of registrant as specified in its charter) Commission File Number: 001-34045 Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| March 15, 2023 |
Enovis Announces Board Leadership Transition EX-99.1 Exhibit 99.1 Enovis Announces Board Leadership Transition CEO Matt Trerotola to be named Chair and Director Sharon Wienbar to become Lead Independent Director following retirement of current Chair Mitchell P. Rales at 2023 Annual Meeting WILMINGTON, DE, March 15, 2023 (GLOBE NEWSWIRE)—Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced |
|
| March 1, 2023 |
Subsidiaries of the Registrant EXHIBIT 21.1 Subsidiaries of the Registrant Entity Name Jurisdiction 360 EPPA Pty Ltd Australia 360 Hip Systems Pty Limited Australia 360 Knee Systems (NZ) Limited New Zealand 360 Knee Systems Pty Ltd Australia 360 Med Care Pty Ltd Australia Athena Finance Limited Barbados Cefar-Compex Medical AB Sweden Chattanooga Europe, B.V. Belgium Colfax (Wuxi) Pump Company Limited China Colfax Group GmbH Ger |
|
| March 1, 2023 |
December 31, 2022 Mr. Phillip Benjamin (Ben) Berry Via Email Strictly private and confidential Dear Ben, Congratulations! We are very pleased to offer you a promotion to the position of Chief Financial Officer and Senior Vice President, Enovis Corporation, reporting directly to me. This offer has been approved by the Compensation and Human Capital Management Committee of the Board of Directors. We |
|
| March 1, 2023 |
March 5, 2021 Patricia Lang 420 National Business Parkway 5th Floor Annapolis Junction, MD 20701 Re: Retention Agreement Dear Patty: In light of the strategic decision Colfax Corporation (“Colfax”) has made to separate its ESAB and DJO businesses into two independent, publicly-traded companies (the “Transaction”), Colfax considers your continued services to be essential to protecting and enhancing the best interests of Colfax and its stockholders. |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34045 ENOVIS CORPORATION (Exact |
|
| March 1, 2023 |
[Remainder of page left intentionally blank] December 31, 2022 Mr. Christopher M. Hix [Address on file with the Company] Re: CFO Retirement Transition Agreement Dear Chris: This Transition and Retirement Agreement (this “Agreement”) sets forth the understanding between you and Enovis Corporation (the “Company”) regarding your continued employment as Chief Financial Officer of the Company and your planned retirement and transition. On behalf |
|
| March 1, 2023 |
December 14, 2018 Ms. Patty Lang Via Email Strictly private and confidential Dear Patty, Congratulations! We are very pleased to extend you an employment offer for the position of Chief Human Resource Officer and Senior Vice President, Colfax Corporation, reporting to Matthew Trerotola, President and CEO, Colfax Corporation. This offer has been approved by the Board of Directors and is valid until |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction (Commission (I.R.S. Employer of |
|
| February 23, 2023 |
Enovis Announces Fourth Quarter and Full Year 2022 Results EX-99.1 2 q42022earningspressrelease.htm EX-99.1 Enovis Announces Fourth Quarter and Full Year 2022 Results •Completed first year as independent Med Tech growth company with sales growth of 10%, organic growth of 6% and EBITDA margin expansion •Grew fourth quarter sales 2% to $409 million, with 5% organic growth over the prior year quarter, and double-digit growth performance in its Reconstructive |
|
| February 13, 2023 |
ENOV / / RALES MITCHELL P - SC 13G/A Passive Investment SC 13G/A 1 d460522dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2. Under the Securities Exchange Act of 1934 (Amendment No. 11)* Enovis Corporation (Name of Issuer) Common Stock, par value $0.001 per s |
|
| February 13, 2023 |
ENOV / / Durable Capital Partners LP - AMENDMENT TO FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Enovis Corporation (Name of Issuer) Common Stock, $0.001 per share (Title of Class of Securities) 194014502 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| February 10, 2023 |
ENOV / / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Enovis Corp (Name of Issuer) Common Stock (Title of Class of Securities) 194014502 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 9, 2023 |
ENOV / / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Enovis Corp. Title of Class of Securities: Common Stock CUSIP Number: 194014502 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1 |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2022 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 15, 2022 |
Amended and Restated Bylaws of Enovis Corporation, effective as of December 13, 2022. EX-3.1 Exhibit 3.1 ENOVIS CORPORATION AMENDED AND RESTATED BYLAWS Adopted Effective as of December 13, 2022 TABLE OF CONTENTS 1. OFFICES 1 1.1 Registered Office 1 1.2 Other Offices 1 2. MEETINGS OF STOCKHOLDERS 1 2.1 Place of Meetings 1 2.2 Annual Meetings 1 2.2.1 Stockholder Proposed Business 2 2.2.2 Requirement to Update and Supplement 5 2.2.3 Requirements for Entities 5 2.2.4 Requiremen |
|
| December 6, 2022 |
CORRESP 1 filename1.htm 2711 Centerville Road Suite 400 Wilmington, Delaware 19808 United States enovis.com December 6, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Kristin Lochhead and Brian Cascio Re: Enovis Corporation Form 10-K for the Fiscal Year En |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2022 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction (Commission (I.R.S. Employer of |
|
| November 2, 2022 |
Exhibit 31.01 CERTIFICATIONS I, Matthew L. Trerotola, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number - 001-34045 Enovis Corporat |
|
| November 2, 2022 |
Enovis Announces Third Quarter 2022 Results Enovis Announces Third Quarter 2022 Results •Grew sales to $384 million, including 7% organic growth over the prior year quarter, with double-digit growth performance across its Reconstructive segment •Reported a net loss of $(1. |
|
| November 2, 2022 |
Exhibit 32.02 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Christopher M. Hix, as Executive Vice President, Finance, Chief Financial Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.th |
|
| November 2, 2022 |
Exhibit 31.02 CERTIFICATIONS I, Christopher M. Hix, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with r |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction (Commission (I.R.S. Employer of i |
|
| November 2, 2022 |
Exhibit 32.01 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Matthew L. Trerotola, as President and Chief Executive Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.the quarterly report |
|
| September 20, 2022 |
ENOV / / RALES STEVEN M - AMENDMENT NO. 7 TO SC 13G Passive Investment Amendment No. 7 to SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2. Under the Securities Exchange Act of 1934 (Amendment No. 7)* Enovis Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title |
|
| August 24, 2022 |
Exhibit 99.1 Notice of Blackout Period Under the Enovis Corporation 401(k) Savings Plan Plus (As Required by Rule 104 Under SEC Regulation Blackout Trading Restriction) To: All Directors and Section 16 Officers of Enovis Corporation From: Brian Hanigan, Vice President and Corporate Secretary Date: August 24, 2022 Subject: Notice of Blackout Trading Restriction Period (the ?BTR Blackout Period?) Cl |
|
| August 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2022 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File |
|
| August 4, 2022 |
Exhibit 32.01 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Matthew L. Trerotola, as President and Chief Executive Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.the quarterly report |
|
| August 4, 2022 |
As filed with the Securities and Exchange Commission on August 4, 2022 As filed with the Securities and Exchange Commission on August 4, 2022 Registration No. |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction (Commission (I.R.S. Employer of inc |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended July 1, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number - 001-34045 Enovis Corporation (E |
|
| August 4, 2022 |
Exhibit 31.01 CERTIFICATIONS I, Matthew L. Trerotola, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| August 4, 2022 |
EX-FILING FEES 4 d363084dexfilingfees.htm EX-FILING FEES Exhibit 107 Form S-8 (Form Type) ENOVIS CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity C |
|
| August 4, 2022 |
Exhibit 31.02 CERTIFICATIONS I, Christopher M. Hix, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with r |
|
| August 4, 2022 |
Enovis Announces Second Quarter 2022 Results Enovis Announces Second Quarter 2022 Results ?Sales of $395 million include 11% reported growth, 3% organic growth and 5% sales-per-day growth ?Reported operating income of $6 million, while adjusted EBITDA increased 11% to $56 million ?Reported earnings per diluted share from continuing operations of $2. |
|
| August 4, 2022 |
Exhibit 32.02 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Christopher M. Hix, as Executive Vice President, Finance, Chief Financial Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.th |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2022 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 30, 2022 |
Enovis Announces Chief Financial Officer Transition Plan Exhibit 99.1 Enovis Announces Chief Financial Officer Transition Plan Wilmington, Delaware, June 30, 2022 ? Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced that Ben Berry, CFO of the Company?s business units, will succeed Chris Hix as Chief Financial Officer, effective January 1, 2023. At that time, Mr. Hix will transition to an advisory rol |
|
| June 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number - 001-34045 A. Full title of the plan and the ad |
|
| June 13, 2022 |
EXHIBIT 10.1 FIRST AMENDMENT TO THE ENOVIS CORPORATION 2020 OMNIBUS INCENTIVE PLAN WHEREAS, Enovis Corporation, a Delaware corporation, formerly named Colfax Corporation (the ?Company?), established and sponsors the Enovis Corporation 2020 Omnibus Incentive Plan (the ?Plan?); WHEREAS, pursuant to Section 5.3 of the Plan, the Board of Directors of the Company (the ?Board?) reserved the right to ame |
|
| June 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 31, 2022 |
United States Securities and Exchange Commission Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 (State or other jurisdiction (Commission file of incorporation) number) 2711 Centerville Road, Suite 400 Wilmington, DE 19808 20701 (Address of principal executive offices) (Zip code) Bradley J. Ta |
|
| May 31, 2022 |
Exhibit 1.01 Conflict Minerals Report Enovis Corporation has included this Conflict Minerals Report as an exhibit to its Form SD for the period from January 1st 2021 to December 31st 2021 as provided for in Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and Form SD (collectively, the ?Conflict Minerals Rule?). The date of filing of this Conflict Minerals Report is May 28, 2022. |
|
| May 10, 2022 |
Exhibit 32.01 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Matthew L. Trerotola, as President and Chief Executive Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.the quarterly report |
|
| May 10, 2022 |
Exhibit 31.02 CERTIFICATIONS I, Christopher M. Hix, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with r |
|
| May 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 10, 2022 |
Exhibit 31.01 CERTIFICATIONS I, Matthew L. Trerotola, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Enovis Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| May 10, 2022 |
Exhibit 32.02 Certification Pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002) I, Christopher M. Hix, as Executive Vice President, Finance, Chief Financial Officer of Enovis Corporation (the “Company”), certify, pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002), that to my knowledge: 1.th |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended April 1, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number - 001-34045 Enovis Corporation ( |
|
| May 10, 2022 |
Enovis Announces First Quarter 2022 Adjusted Stand-Alone Results Exhibit 99.1 Enovis Announces First Quarter 2022 Adjusted Stand-Alone Results ? Increased stand-alone sales 21% to $375 million; organic growth of 7% ? Grew adjusted stand-alone EBITDA 25% to $48 million ? Achieved adjusted stand-alone earnings per diluted share of $0.37 ? Reaffirmed 2022 guidance for EBITDA of $245 to $265 million and adjusted EPS in the range of $2.20 to $2.40 WILMINGTON, DE, Ma |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 28, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Enovis Corporation (Name of Issuer) Common Stock, $0.001 per share (Title of Class of Securities) 194014502 (CUSIP Number) April 11, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| April 8, 2022 |
EBS License Agreement, dated April 4, 2022, between Enovis Corporation and ESAB Corporation Exhibit 10.5 EXECUTION VERSION EBS LICENSE AGREEMENT BY AND BETWEEN COLFAX CORPORATION AND ESAB CORPORATION DATED AS OF APRIL 4, 2022 TABLE OF CONTENTS ARTICLE I. DEFINITIONS 1 1.1 Certain Defined Terms 1 1.2 Interpretation 3 ARTICLE II. LICENSE GRANT 4 2.1 License to ESAB 4 2.2 License to Enovis 4 2.3 Provision of Improvements 4 ARTICLE III. INTELLECTUAL PROPERTY RIGHTS 4 3.1 Enovis Ownership 4 3 |
|
| April 8, 2022 |
Enovis (formerly Colfax) Completes Spin-off of ESAB Corporation Exhibit 99.1 Enovis (formerly Colfax) Completes Spin-off of ESAB Corporation WILMINGTON, DE, April 5, 2022 (GLOBE NEWSWIRE)?Enovis Corporation (?Enovis? or the ?Company?) (NYSE: ENOV), an innovation-driven medical technology growth company formerly known as Colfax Corporation, announced today the completion of its previously announced separation (the ?Separation?) of its fabrication technology bus |
|
| April 8, 2022 |
Exhibit 10.4 EXECUTION VERSION INTELLECTUAL PROPERTY MATTERS AGREEMENT BY AND BETWEEN COLFAX CORPORATION AND ESAB CORPORATION DATED AS OF APRIL 4, 2022 TABLE OF CONTENTS ARTICLE I. DEFINITIONS 1 1.1 Definitions 1 1.2 Interpretation 4 ARTICLE II. GRANT OF RIGHTS 5 2.1 License to ESAB of Enovis Licensed IP 5 2.2 License to Enovis of ESAB Licensed IP 5 2.3 Limitations 5 2.4 Reservation of Rights 5 2. |
|
| April 8, 2022 |
Transition Services Agreement, dated April 4, 2022, between Enovis Corporation and ESAB Corporation Exhibit 10.1 TRANSITION SERVICES AGREEMENT BY AND BETWEEN COLFAX CORPORATION AND ESAB CORPORATION DATED AS OF APRIL 4, 2022 TABLE OF CONTENTS ARTICLE I. DEFINITIONS 1 1.1 Definitions 1 1.2 Interpretation 2 ARTICLE II. SERVICES 3 2.1 Services 3 2.2 Additional Services 3 2.3 Exceptions to Services Obligations 3 2.4 Standard of the Provision of Services 4 2.5 Maintenance 4 2.6 Change in Services 4 2. |
|
| April 8, 2022 |
Employee Matters Agreement, dated April 4, 2022, between Enovis Corporation and ESAB Corporation Exhibit 10.3 EMPLOYEE MATTERS AGREEMENT by and between COLFAX CORPORATION and ESAB CORPORATION Dated as of April 4, 2022 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INTERPRETATION 1 Section 1.1 General 1 Section 1.2 References; Interpretation 7 ARTICLE II GENERAL PRINCIPLES 8 Section 2.1 Nature of Liabilities 8 Section 2.2 Transfers of Employees and Independent Contractors Generally 8 Section |
|
| April 8, 2022 |
Exhibit 3.2 ENOVIS CORPORATION AMENDED AND RESTATED BYLAWS Adopted Effective as of April 4, 2022 TABLE OF CONTENTS 1. OFFICES 1 1.1 Registered Office 1 1.2 Other Offices 1 2. MEETINGS OF STOCKHOLDERS 1 2.1 Place of Meetings 1 2.2 Annual Meetings 1 2.2.1 Stockholder Proposed Business 1 2.2.2 Record Date Requirements 3 2.2.3 Requirements for Entities 4 2.2.4 Requirement to Appear 4 2.2.5 Inapplicabi |
|
| April 8, 2022 |
Exhibit 10.7 EXECUTION VERSION CREDIT AGREEMENT dated as of April 4, 2022 among COLFAX CORPORATION (to be renamed ENOVIS CORPORATION) The Other Loan Parties Party Hereto The Lenders Party Hereto JPMORGAN CHASE BANK, N.A. as Administrative Agent BANK OF AMERICA, N.A. as Syndication Agent CITIZENS BANK, N.A., BNP PARIBAS, BANK OF MONTREAL, WELLS FARGO BANK, NATIONAL ASSOCIATION, CITIBANK N.A., KEYBA |
|
| April 8, 2022 |
Exhibit 10.6 STOCKHOLDER?S AND REGISTRATION RIGHTS AGREEMENT This STOCKHOLDER?S AND REGISTRATION RIGHTS AGREEMENT, dated as of April 4, 2022 (this ?Agreement?), is by and between ESAB Corporation, a Delaware corporation (?ESAB?), and Colfax Corporation (to be renamed Enovis Corporation), a Delaware corporation (?Enovis?). WHEREAS, Enovis currently owns all of the issued and outstanding shares of c |
|
| April 8, 2022 |
Tax Matters Agreement, dated April 4, 2022, between Enovis Corporation and ESAB Corporation Exhibit 10.2 Execution Version TAX MATTERS AGREEMENT BY AND BETWEEN COLFAX CORPORATION AND ESAB CORPORATION DATED AS OF APRIL 4, 2022 TABLE OF CONTENTS Page Section 1. Definition of Terms 2 Section 2. Allocation of Tax Liabilities and Tax-Related Losses 10 Section 2.01 General Rule 10 Section 2.02 General Allocation Principles 11 Section 2.03 Allocation Conventions 12 Section 3. Preparation and Fi |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 Enovis Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File N |
|
| April 8, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF COLFAX CORPORATION Colfax Corporation (the ?Corporation?), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify as follows: FIRST: The Amended and Restated Certificate of Incorporation of the |
|
| April 8, 2022 |
Exhibit 2.1 EXECUTION VERSION SEPARATION AND DISTRIBUTION AGREEMENT BY AND BETWEEN COLFAX CORPORATION AND ESAB CORPORATION DATED AS OF APRIL 4, 2022 TABLE OF CONTENTS ARTICLE I. DEFINITIONS 2 1.1 Definitions 2 1.2 Interpretation 14 ARTICLE II. SEPARATION 15 2.1 Transfers of Assets and Assumptions of Liabilities; ESAB Assets; Enovis Assets 15 2.2 Nonassignable Contracts and Permits 20 2.3 Terminati |
|
| April 8, 2022 |
Exhibit 99.2 Unaudited Pro Forma Condensed Consolidated Financial Information On April 4, 2022, Colfax Corporation (?Colfax?, the ?Company?, ?we?, ?our?, and ?us?), a Delaware corporation, completed the previously announced separation of its Fabrication Technology business, into a separate, independent publicly traded company, ESAB Corporation (?ESAB?). The separation was structured as a spin-off, |
|
| March 14, 2022 |
March 14, 2022 Investor Presentation Enovis: An Innovation Driven Medical Technology Company Exhibit 99. |
|
| March 14, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2022 Colfax Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File |
|
| March 14, 2022 |
Exhibit 99.2 DISCLAIMER This document has been prepared by ESAB Corporation, a Delaware corporation (the ?Company? or ?ESAB?), solely for informational purposes. Upon completion of the intended separation of Colfax Corporation?s (?Colfax?) fabrication technology and specialty medical technology businesses (the ?Separation?), ESAB will hold the fabrication technology business and become an independ |
|
| March 14, 2022 |
Colfax Announces Expected Completion Date of April 4, 2022 for Spin-Off of ESAB Corporation Exhibit 99.1 Colfax Announces Expected Completion Date of April 4, 2022 for Spin-Off of ESAB Corporation ? ?When-issued? trading of ESAB and Colfax ex-distribution common stock expected to begin on March 21, 2022 ? Record date for distribution of ESAB common stock will be March 22, 2022 ? Distribution Date expected to be April 4, 2022 WILMINGTON, DE, March 14, 2022 (GLOBE NEWSWIRE)?Colfax Corporat |
|
| March 14, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2022 Colfax Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File |
|
| March 11, 2022 |
EXHIBIT 99.2 Formal Notice of Blackout Period Under the Colfax Corporation 401(k) Savings Plan Plus The ESAB Group, Inc. 401(k) Retirement Savings Plan (As Required Under Section 306(a)(6) of the Sarbanes-Oxley Act of 2002) To: All Executive Officers and Directors of Colfax Corporation and ESAB Corporation From: Colfax Corporation Date: March 7, 2022 Subject: Notice of Trading Blackout Period This |
|
| March 11, 2022 |
Colfax Announces Board of Directors for Enovis, the Post-Spinoff Medical Technology Company Exhibit 99.1 Colfax Announces Board of Directors for Enovis, the Post-Spinoff Medical Technology Company WILMINGTON, DE, March 11, 2022 (GLOBE NEWSWIRE) ? Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced the future composition of the Board of Directors (the ?Board?) of the Company, which will be renamed Enovis Corporation (?Enovis?) upon the consummation of |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2022 Colfax Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 1, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Colfax Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2022 Colfax Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 25, 2022 |
EXECUTIVE EMPLOYMENT AGREEMENT EX-99.1 2 d185082dex991.htm EX-99.1 Exhibit 99.1 EXECUTIVE EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is entered into as of the 21st day of February, 2022, by and among ESAB Corporation, a Delaware corporation (the “Company”) and Shyam Kambeyanda, an individual (the “Executive”). WHEREAS, the Company desires to employ the Executive as the President and Chief Executive Officer of |
|
| February 22, 2022 |
Exhibit 10.32 AMENDMENT NUMBER THREE COLFAX CORPORATION NONQUALIFIED DEFERRED COMPENSATION PLAN The Colfax Corporation Nonqualified Deferred Compensation Plan, effective January 1, 2016 and as subsequently amended (together, the ?Plan?), is hereby further amended as follows, effective as of December 1, 2020: 1. Section 15.17 is hereby deleted in its entirety and amended and restated as follows: ?D |
|
| February 22, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022 Colfax Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction (Commission (I.R.S. Employer of |
|
| February 22, 2022 |
Subsidiaries of the Registrant EX-21.1 6 exhibit211subsidiariesofre.htm EX-21.1 Subsidiaries of the Registrant Exhibit 21.1 Entity Name Country Agridzaar Limited Cyprus Airgare Limited United Kingdom Arc Machines GmbH Germany AS ESAB Norway Canadian Cylinder Company Ltd. Canada CAST Limited United Kingdom CAST Resources Limited United Kingdom Cefar-Compex Medical AB Sweden Central Mining Finance Limited United Kingdom Charter C |
|
| February 22, 2022 |
Exhibit 10.33 AMENDMENT NUMBER FOUR COLFAX CORPORATION NONQUALIFIED DEFERRED COMPENSATION PLAN The Colfax Corporation Nonqualified Deferred Compensation Plan, effective January 1, 2016 and as subsequently amended (together, the ?Plan?), is hereby further amended as follows, effective as of January 1, 2022: 1.Section 1.10 is hereby deleted in its entirety and amended and restated as follows: ?1.10 |
|
| February 22, 2022 |
EX-4.8 2 exhibit48-descriptionofsec.htm EX-4.8 EXHIBIT 4.8 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Colfax Corporation (the “Company”, “we”, “us” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, $0.001 par value per s |
|
| February 22, 2022 |
AMENDMENT NO. 4 TO COLFAX CORPORATION REGISTRATION RIGHTS AGREEMENT February 22, 2022 Exhibit 10.54 AMENDMENT NO. 4 TO COLFAX CORPORATION REGISTRATION RIGHTS AGREEMENT February 22, 2022 This Amendment No. 4 (this ?Amendment?), dated as of February 22, 2022 (the ?Effective Date?), to that certain Registration Rights Agreement (the ?Agreement?), dated as of May 30, 2003, by and among Colfax Corporation, a Delaware corporation (the ?Company?), and Mitchell P. Rales and Steven M. Rales |
|
| February 22, 2022 |
Colfax Corporation Announces Fourth Quarter and Full Year 2021 Results EX-99.1 2 q42021earningspressrelease.htm EX-99.1 Colfax Corporation Announces Fourth Quarter and Full Year 2021 Results •Strong operating performance supported $0.06 EPS from continuing operations and $0.59 of adjusted EPS •Achieved a strong quarter of cash flow, contributing to full year operating cash flow of $356 million and free cash flow of $277 million •Positioned for separation into two ind |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-34045 COLFAX CORPORATION (Exact nam |
|
| February 14, 2022 |
CFX / Colfax Corp / RALES STEVEN M - AMENDMENT NO. 6 TO SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2. Under the Securities Exchange Act of 1934 (Amendment No. 6)* Colfax Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 19 |
|
| February 9, 2022 |
CFX / Colfax Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Colfax Corp. Title of Class of Securities: Common Stock CUSIP Number: 194014106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1 |
|
| February 8, 2022 |
CFX / Colfax Corp / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Colfax Corp (Name of Issuer) Common Stock (Title of Class of Securities) 194014106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2022 Colfax Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 26, 2022 |
CFXA / Colfax Corporation 5.75% Tangible Equity Units / WELLS FARGO & COMPANY/MN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) COLFAX CORP (Name of Issuer) UNIT 01/15/2022T (Title of Class of Securities) 194014205 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 18, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| January 18, 2022 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on January 31, 2022, pursuant to the provisions of Rule 12d2-2 (a). |
|
| January 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2022 Colfax Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 7, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| December 30, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2021 Colfax Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 30, 2021 |
Colfax Announces Plans for Reverse Stock Split Exhibit 99.1 Colfax Announces Plans for Reverse Stock Split WILMINGTON, DE, December 30, 2021 (GLOBE NEWSWIRE) ? Colfax Corporation (?Colfax? or the ?Company?) (NYSE: CFX), a leading diversified technology company, announced today that it plans to hold a special meeting of stockholders to seek approval for an amendment to the Company?s Amended and Restated Certificate of Incorporation (the ?Certif |
|
| December 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2021 Colfax Corporation (Exact name of registrant as specified in its charter) Delaware 001-34045 54-1887631 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 4, 2021 |
Exhibit 31.01 CERTIFICATIONS I, Matthew L. Trerotola, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Colfax Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| November 4, 2021 |
Colfax Corporation Announces Third Quarter 2021 Results Colfax Corporation Announces Third Quarter 2021 Results ?Posted $0.17 EPS from continuing operations and $0.54 of adjusted EPS ?Increased sales 20% to $966 million including a 15% organic sales-per-day improvement ?Reported strong progress on integration of acquisitions ?Announced continued progress to Q1 2022 separation including new post-separation name for MedTech growth company WILMINGTON, DE, |
|
| November 4, 2021 |
Exhibit 31.02 CERTIFICATIONS I, Christopher M. Hix, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Colfax Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with r |
